EKSO

Ekso Bionics Holdings Inc

EKSO, USA

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EVO, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. It also offers EksoCare offering an extended warranty and premium service options, repairs and maintenance services, and training programs. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.

https://www.eksobionics.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
EKSO
stock
EKSO

Ekso Bionics Raises $5.9 Million via Convertible Preferred and Warrants in Private Placement TipRanks

Read more →
EKSO
stock
EKSO

Ekso Bionics raises $5.9 million in private stock placement By Investing.com Investing.com Canada

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$9.5

Analyst Picks

Strong Buy

1

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

High

2.41

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-14.68 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-6.56 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-49.94 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.24

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 1.16% of the total shares of Ekso Bionics Holdings Inc

1.

Fidelity Extended Market Index

(0.3627%)

since

2025/07/31

2.

Vanguard Institutional Extnd Mkt Idx Tr

(0.3147%)

since

2025/07/31

3.

World Impact SICAV Imptt Glbl Eq IEURAcc

(0.1404%)

since

2025/03/31

4.

Fidelity Series Total Market Index

(0.0798%)

since

2025/07/31

5.

Fidelity Total Market Index

(0.0379%)

since

2025/07/31

6.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.036%)

since

2024/12/31

7.

NT Ext Equity Mkt Idx Fd - NL

(0.0309%)

since

2025/06/30

8.

Spartan Total Market Index Pool G

(0.0299%)

since

2025/07/31

9.

NT Ext Equity Mkt Idx Fd - L

(0.0294%)

since

2025/06/30

10.

Northern Trust Extended Eq Market Idx

(0.0294%)

since

2025/06/30

11.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.024%)

since

2025/06/30

12.

Extended Equity Market Fund K

(0.0149%)

since

2025/06/30

13.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0083%)

since

2025/06/30

14.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.007%)

since

2024/12/31

15.

State St US Extended Mkt Indx NL Cl C

(0.0045%)

since

2025/08/31

16.

State St US Ttl Mkt Indx NL Cl A

(0.0038%)

since

2025/08/31

17.

Northern Trust Wilshire 5000

(0.0031%)

since

2025/06/30

18.

Spartan Extended Market Index Pool F

(0.0026%)

since

2025/07/31

19.

SSgA U.S. Total Market Index Strategy

(0.0019%)

since

2025/03/31

20.

Extended Equity Market Fund M

(0.0019%)

since

2025/06/30

21.

TWO SIGMA SECURITIES, LLC

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.54

EPS Estimate

-0.965

EPS Difference

0.425

Surprise Percent

44.0415%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2.5)
Defensive
Moderately Defensive(6)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Fair GARP(3.5)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(2)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.